CutPRO® Cut Resistant Clothing Sponsoring Leading Glass Event ‘Glass Focus 2019’
19.11.2019 11:00:00 EET | Business Wire | Press release
British firm CutPRO® is sponsoring this year’s ‘Glass Focus 2019’ event taking place on 21 November in Sheffield, United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005029/en/
CutPRO® is a pioneering British brand of high performance cut resistant clothing, providing fully CE certified, EN 388:2016 tested and thoroughly field tested cut protection. (Graphic: Business Wire)
Robert Kaiser, CEO of PPSS Group, the firm behind the CutPRO® brand, also announced it had entered the ‘Health and Safety Action’ category: “We have high hopes to win this prestigious award. Our innovative and pioneering brand of high performance cut resistant clothing somewhat deserves that level of recognition”.
The event is organised by ‘British Glass’, the representative body for the UK industry. Communicating the glass sector’s values and interests, their aim is to secure a thriving and sustainable future.
UK based PPSS Group has been producing cut resistant clothing for the past ten years, its sole purpose being the protection of frontline professionals in sectors where cuts and lacerations are a high risk e.g. homeland security.
In February 2018 the now highly acclaimed CutPRO® brand was launched, again using their very own Cut-Tex® PRO cut resistant fabric. Cut-Tex® PRO has achieved outstanding levels of cut, tear, abrasion and puncture resistance, while being extremely durable, lightweight and rather comfortable.
As a single layer it is offering ANSI/ISEA 2016 Blade Cut Resistance Level A5.
CutPRO®s Senior Product Consultant Eve Ichim operated as a liaison between potential customers and the firm’s production team, gathering relevant information about precise requirements and preferences for cut resistant clothing.
Based on this information, extensive market research and working together with the multi-award-winning Department of Apparel from one UK’s leading Universities, CutPRO® is now offering the ultimate garment designs, taking 'durability' and 'quality' to a completely different level.
All garments are manufactured in the E.U. and are fully CE marked and certified (Cat II PPE). This means they fully comply with European laws, rules and regulations.
All garments have also been successful assessed against the updated and latest EN 388:2016 standard, confirming the following performance levels: Cut Resistance Level E (Level 5 on previous standard). Puncture Resistance Level 4. Tear Resistance Level 4. Abrasion Resistance Level 3.
If you are planning to attend the ‘Glass Focus 2019’ go and say hi to their team. You will be welcomed with open arms and an immense level of technical knowledge.
Robert Kaiser has also recently announced his company’s participation at next year’s glasstec2020 Expo in Dusseldorf, Germany:
"We have decided to present and exhibit our truly outstanding cut resistant clothing range at glasstec2020, the world’s largest and most respected Exhibition within the glass industry."
"There is no better platform for us to showcase our range of potentially lifesaving cut resistant garments to the world."
In case you have any questions in reference to cut resistant clothing, please email info@cut-pro.com or visit www.cut-pro.com.
END
About CutPRO®
CutPRO® Cut Resistant Clothing is a pioneering brand of highly protective clothing. Made from the world’s most reliable, fully certified and thoroughly field-tested cut resistant fabric Cut-Tex® PRO. The company’s social media presence: Facebook, LinkedIn, Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005029/en/
Contact information
Ryan Vickers, CDO
PPSS Group / CutPRO®
info@ppss-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 09:00:00 EEST | Press release
Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to digital to manage their businesses. In late 2025, Tide received a strategic investment from TPG, a leading global alternative asset manager, valuing the company at $1.5 billion. Oliver Prill, CEO of Tide, said: “We are delighted to be crossing the 2 million member milestone. This number is a testament to the trust that our members place in us in all our markets. Behind every
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom